These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 8211798)
41. Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA). Ito JI; Chandrasekar PH; Hooshmand-Rad R Bone Marrow Transplant; 2005 Nov; 36(10):873-7. PubMed ID: 16113663 [TBL] [Abstract][Full Text] [Related]
42. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Lissia M; Figus A; Rubino C Br J Plast Surg; 2005 Jun; 58(4):504-10. PubMed ID: 15897036 [TBL] [Abstract][Full Text] [Related]
43. Effect of different LDL-apheresis methods on parameters involved in atherosclerosis. Hershcovici T; Schechner V; Orlin J; Harell D; Beigel Y J Clin Apher; 2004; 19(2):90-7. PubMed ID: 15274202 [TBL] [Abstract][Full Text] [Related]
44. [Treatment of thrombocytopenic thrombotic purpura]. Corte Buelga JR; Rodríguez Vicente P; García Gala JM; Alonso García AM; Martínez Revuelta E Sangre (Barc); 1997 Feb; 42(1):53-61. PubMed ID: 9229804 [No Abstract] [Full Text] [Related]
45. Adjunctive use of plasmapheresis and intravenous immunoglobulin therapy in sepsis: a case report. Kyles DM; Baltimore J Am J Crit Care; 2005 Mar; 14(2):109-12. PubMed ID: 15728952 [No Abstract] [Full Text] [Related]
46. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. Jayne DR; Gaskin G; Rasmussen N; Abramowicz D; Ferrario F; Guillevin L; Mirapeix E; Savage CO; Sinico RA; Stegeman CA; Westman KW; van der Woude FJ; de Lind van Wijngaarden RA; Pusey CD; J Am Soc Nephrol; 2007 Jul; 18(7):2180-8. PubMed ID: 17582159 [TBL] [Abstract][Full Text] [Related]
47. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Danieli MG; Cappelli M; Malcangi G; Logullo F; Salvi A; Danieli G Ann Rheum Dis; 2004 Dec; 63(12):1649-54. PubMed ID: 15547090 [TBL] [Abstract][Full Text] [Related]
48. Lipid emulsion for the treatment of local anesthetic toxicity: patient safety implications. Brull SJ Anesth Analg; 2008 May; 106(5):1337-9. PubMed ID: 18420840 [No Abstract] [Full Text] [Related]
49. Long-term clinical outcomes of synchronized therapy with plasmapheresis and intravenous cyclophosphamide pulse therapy in the treatment of steroid-resistant lupus nephritis. Yamaji K; Kim YJ; Tsuda H; Takasaki Y Ther Apher Dial; 2008 Aug; 12(4):298-305. PubMed ID: 18789117 [TBL] [Abstract][Full Text] [Related]
53. [Peripheral arterial occlusive disease--initial therapy in general practice]. Klimm HD Fortschr Med; 1993 Apr; 111(11):181-2. PubMed ID: 8508993 [No Abstract] [Full Text] [Related]
54. Severe and common side-effects of amphotericin B lipid complex (Abelcet). Ringdén O; Jønsson V; Hansen M; Tollemar J; Jacobsen N Bone Marrow Transplant; 1998 Oct; 22(7):733-4. PubMed ID: 9818706 [No Abstract] [Full Text] [Related]
55. Evidence of combined therapy of dyslipoproteinemia by HMG-CoA reductase inhibitors and "essential" phospholipids. Gurevich VS; Bondarenko BB; Mikhailova IA; Kasennova NI; Popov YuG ; Astashkina ; Le Van Thach TD Clin Ter; 1993 Apr; 142(4):329-34. PubMed ID: 8330475 [TBL] [Abstract][Full Text] [Related]
56. The treatment of severe forms of myasthenia gravis. Iani C; Caramia M; Morosetti M; Loberti M; Palmieri MG; Meloni C; Gallucci MT; Casciani CU; Bernardi G Funct Neurol; 1998; 13(3):231-7. PubMed ID: 9800150 [TBL] [Abstract][Full Text] [Related]
57. Lipid emulsion as antidotal therapy--ready to register? Cave G; Harvey M Crit Care Med; 2009 Jul; 37(7):2325-6; author reply 2326. PubMed ID: 19535941 [No Abstract] [Full Text] [Related]
58. [Ischemic renal disease: revascularization or conservative treatment?]. Rodríguez Jornet A; Ibeas J; Ribera L; Real J; Perendreu J; Falcó J; Vallespín J; Allegué N; Giménez Gaibar A; García García M Nefrologia; 2005; 25(3):258-68. PubMed ID: 16053007 [TBL] [Abstract][Full Text] [Related]
59. Reversible dilated cardiomyopathy related to amphotericin B therapy. Danaher PJ; Cao MK; Anstead GM; Dolan MJ; DeWitt CC J Antimicrob Chemother; 2004 Jan; 53(1):115-7. PubMed ID: 14657095 [TBL] [Abstract][Full Text] [Related]
60. [The effect of plasmapheresis and other immunomodulating therapies on the course of severe Guillain-Barré syndrome]. Hidasi E; Soltész P Orv Hetil; 2001 Feb; 142(7):335-9. PubMed ID: 11243015 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]